PA
RXDX
Perceptive Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,272,694
| Closed | -$137M | – | 108 |
|
|
2023
Q1 | $137M | Buy |
1,272,694
+60,000
| +5% | +$6.44M | 4.03% | 6 |
|
|
2022
Q4 | $133M | Sell |
1,212,694
-255,818
| -17% | -$28.1M | 3.75% | 5 |
|
|
2022
Q3 | $86.7M | Sell |
1,468,512
-213,730
| -13% | -$12.6M | 2.52% | 13 |
|
|
2022
Q2 | $47.5M | Sell |
1,682,242
-758,340
| -31% | -$21.4M | 1.49% | 15 |
|
|
2022
Q1 | $92.2M | Sell |
2,440,582
-732,203
| -23% | -$27.6M | 1.85% | 13 |
|
|
2021
Q4 | $125M | Sell |
3,172,785
-141,247
| -4% | -$5.58M | 1.93% | 12 |
|
|
2021
Q3 | $78.6M | Hold |
3,314,032
| – | – | 1.14% | 24 |
|
|
2021
Q2 | $81.4M | Hold |
3,314,032
| – | – | 1.06% | 26 |
|
|
2021
Q1 | $55.4M | Buy |
+3,314,032
| New | +$55.4M | 0.7% | 38 |
|